MP03-08 COMPREHENSIVE ANALYSIS AND VALIDATION OF CONTEMPORARY SURVIVAL PROGNOSTICATORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPY

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) I1 Apr 2016MP03-08 COMPREHENSIVE ANALYSIS AND VALIDATION OF CONTEMPORARY SURVIVAL PROGNOSTICATORS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TARGETED THERAPY Kyo Chul Koo, Kwang Suk Lee, Kang Su Cho, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung, and Dong Hyeon Lee Kyo Chul KooKyo Chul Koo More articles by this author , Kwang Suk LeeKwang Suk Lee More articles by this author , Kang Su ChoKang Su Cho More articles by this author , Koon Ho RhaKoon Ho Rha More articles by this author , Sung Joon HongSung Joon Hong More articles by this author , Byung Ha ChungByung Ha Chung More articles by this author , and Dong Hyeon LeeDong Hyeon Lee More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.1901AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES In line with the era of targeted-therapy (TT), an increasing number of prognosticators are becoming available for patients with metastatic renal cell carcinoma (mRCC). Here, potential prognosticators of cancer-specific survival (CSS) were identified based on the contemporary literature, and were comprehensively validated in an independent cohort of patients treated for mRCC. METHODS Data were collected from 478 patients treated with TT for mRCC between January 1999 and July 2013 at a single institution. The analysis included 24 clinicopathological covariates that included both traditional and contemporary prognosticators: age, sex, body mass index, Karnofsky performance status (KPS), Charlson Comorbidity Index, anemia, neutrophilia, neutrophil-to-lymphocyte ratio (NLR), thrombocytosis, hypercalcemia, T and N stages, tumor size, grade, subtype, sarcomatoid feature, tumor thrombus, number and location of metastasis, lymph node metastasis (supradiaphragmatic vs. subdiaphragmatic), cytoreductive nephrectomy, time from diagnosis to TT, number of TT lines, and tumor response following TT. Multivariate Cox-regression models were used to quantify the effect of covariates on CSS. RESULTS Median survival from the initial diagnosis of metastasis was 24.5 (IQR 11.5-55.7) months. There were 303 (63.4%) cancer-specific deaths, yielding a 2-year CSS rate of 62.5%. Low KPS, hypercalcemia, NLR, the number of metastatic sites (≥2), and the presence of brain metastases were independent adverse prognosticators of CSS. Patients with at least one adverse prognosticator demonstrated lower 2-year CSS rates compared to those with no prognosticators (53.9% vs. 70.6%; log-rank p<0.001). CONCLUSIONS Together with traditional prognosticators such as KPS and hypercalcemia, the number and location of metastases and NLR were independent predictors of CSS in patients with mRCC treated with TT. Our findings could be useful for guiding clinical decision-making including stratification of patients for TT and inclusion in clinical trials. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e21-e22 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Kyo Chul Koo More articles by this author Kwang Suk Lee More articles by this author Kang Su Cho More articles by this author Koon Ho Rha More articles by this author Sung Joon Hong More articles by this author Byung Ha Chung More articles by this author Dong Hyeon Lee More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...